(RTTNews) - ProMIS Neurosciences (PMN) announced the FDA has granted Fast Track designation to PMN310, the company's lead therapeutic candidate in development for the treatment of Alzheimers disease. The company said the designation enables enhanced engagement with the FDA.
The ongoing PRECISE-AD Phase 1b trial is evaluating PMN310 in patients with early AD. ProMIS expects reporting interim six-month biomarker and safety data in second quarter of 2026 and final results in fourth quarter of 2026.
Shares of ProMIS are up 150% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
